These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34429586)

  • 1. The Clinical Efficacy of Three Different Follicle-Stimulating Hormones for Follicle Growth and Development in Long-Protocol Controlled Ovarian Hyperstimulation Treatment.
    Zhang XQ; Zhang LJ; Zhu XL; Xu H; Luo YQ; Yao L; Huang QW; Nong YQ; Liu WJ; Liu FH
    Drug Des Devel Ther; 2021; 15():3573-3580. PubMed ID: 34429586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
    Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
    J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the degree of follicular diameter ≥18mm differentiation on the day of hCG administration to the outcome of controlled ovarian hyperstimulation (COH).
    Xu H; Chen Q; Tian J; Chen X; Zhang X; Li X; Wu Y; Zhang C; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1414213. PubMed ID: 39006360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Repeated superovulation induction after failure in previous IVF-ET cycles with the ultra-long protocol: Analysis of outcomes of clinical pregnancy].
    Wang B; Kong N; Liu JY; Zhang NY; Zhu YC; Zhou JJ
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1099-1102. PubMed ID: 29738181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
    Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
    Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
    Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
    Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing high-order multiple pregnancies during controlled ovarian hyperstimulation and intrauterine insemination: 3 years' experience using low-dose recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.
    Ragni G; Caliari I; Nicolosi AE; Arnoldi M; Somigliana E; Crosignani PG
    Fertil Steril; 2006 Mar; 85(3):619-24. PubMed ID: 16500328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
    Wang L; Zhang WX; Jiang H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
    Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.